Intellia Therapeutics, Inc. (NTLA) |
|
33.1 -0.89 (-2.62%)
|
09-21 12:30 |
|
Open: |
33.34 |
Pre. Close: |
33.99 |
|
High:
|
33.41 |
Low:
|
32.64 |
|
Volume:
|
342,072 |
Market Cap:
|
2,929(M) |
|
|
|
Technical analysis |
as of: 2023-09-21 12:18:25 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 42.72  One year: 45.56 |
| Support: |
Support1: 32.63 Support2: 27.15 |
| Resistance: |
Resistance1: 36.57 Resistance2: 39 |
| Pivot: |
36.4 |
| Moving Average: |
MA(5): 34.45 MA(20): 36.8
MA(100): 40.67 MA(250): 42.1 |
| MACD: |
MACD(12,26): -1.4 Signal(9): -1.1 |
| Stochastic oscillator: |
%K(14,3): 7.3  %D(3): 7 |
| RSI: |
RSI(14): 24.2 |
| 52-week: |
High: 63.11 Low: 32.43 |
| Average Vol(K): |
3-Month: 749 (K) 10-Days: 771 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NTLA ] has closed below the lower bollinger band by 0.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 7.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
34.99 - 35.24 |
35.24 - 35.42 |
|
Low:
|
33.24 - 33.57 |
33.57 - 33.82 |
|
Close:
|
33.54 - 33.98 |
33.98 - 34.32 |
|
Company Description |
|
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Mon, 18 Sep 2023
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of ... - MarketBeat
Wed, 13 Sep 2023
Intellia Therapeutics Enters Oversold Territory (NTLA) - Nasdaq
Wed, 13 Sep 2023
Workhorse Receives IRS Approval for Commercial Clean Vehicle ... - Best Stocks
Sat, 09 Sep 2023
10 Biotech Stocks with Biggest Upside - Yahoo Finance
Thu, 31 Aug 2023
The 3 Most Promising Biotech Stocks to Own Now - InvestorPlace
Tue, 29 Aug 2023
Discovery Value Fund Sells 11389 Shares of Intellia Therapeutics ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
88 (M) |
| Shares Float |
84 (M) |
|
% Held by Insiders
|
5.3 (%) |
|
% Held by Institutions
|
87.9 (%) |
|
Shares Short
|
7,290 (K) |
|
Shares Short P.Month
|
6,210 (K) |
Stock Financials |
|
EPS
|
-5.41 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
12.51 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-867.2 |
|
Return on Assets (ttm)
|
-23.7 |
|
Return on Equity (ttm)
|
-45.7 |
|
Qtrly Rev. Growth
|
-3.1 |
|
Gross Profit (p.s.)
|
-4.16 |
|
Sales Per Share
|
0.59 |
|
EBITDA (p.s.)
|
-5.11 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-368 (M) |
|
Levered Free Cash Flow
|
-224 (M) |
Stock Valuations |
|
PE Ratio
|
-6.12 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
2.64 |
|
Price to Sales
|
55.22 |
|
Price to Cash Flow
|
-7.96 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
